| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ATF; QPD; UPA; URK; u-PA; BDPLT5 |
| Entrez GeneID | 5328 |
| clone | 6B6A3 |
| WB Predicted band size | 48.5KDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PLAU (AA: 107-379) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于PLAU(uPA)抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*"The role of urokinase-type plasminogen activator (uPA) in cancer metastasis and its inhibition by monoclonal antibodies"*
**作者**：Mignatti P. 等
**摘要**：探讨uPA在肿瘤侵袭和转移中的作用，研究显示针对uPA的单克隆抗体可有效抑制肿瘤细胞的迁移和血管生成，为癌症治疗提供潜在靶点。
2. **文献名称**：*"Development of a novel anti-PLAU antibody for the detection of fibrotic liver disease"*
**作者**：Smith J.K. 等
**摘要**：开发了一种高特异性PLAU抗体，通过免疫组化证实其在肝纤维化模型中能准确标记uPA表达，提示其作为纤维化诊断工具的潜力。
3. **文献名称**：*"PLAU antibody-based therapeutic strategies in ovarian cancer: preclinical validation of target engagement"*
**作者**：Chen L. 等
**摘要**：评估PLAU抗体在卵巢癌模型中的疗效，证明其通过阻断uPA与受体的结合抑制肿瘤生长和腹膜扩散，支持进一步临床转化研究。
4. **文献名称**：*"Prognostic significance of uPA/PLAU expression in breast cancer and antibody-mediated neutralization mechanisms"*
**作者**：Duffy M.J. 等
**摘要**：分析乳腺癌患者中uPA的高表达与不良预后的关联，并通过体外实验验证中和性抗体可抑制uPA的酶活性，提出其作为辅助治疗的可行性。
(注：以上文献为示例，实际引用需根据具体研究补充完整信息。)
**Background of PLAU Antibody**
The PLAU gene encodes urokinase-type plasminogen activator (uPA), a serine protease critical for extracellular matrix degradation and cell migration by activating plasminogen to plasmin. uPA interacts with its receptor (uPAR) and inhibitors (PAI-1/2), forming a system implicated in tissue remodeling, wound healing, and pathological processes like cancer metastasis. Elevated uPA expression correlates with tumor invasiveness, poor prognosis, and therapeutic resistance, making it a biomarker and therapeutic target in oncology.
PLAU antibodies are immunological tools designed to detect and quantify uPA in research and diagnostics. They enable studies of uPA’s role in cancer progression, angiogenesis, and inflammation via techniques like immunohistochemistry, ELISA, and Western blot. These antibodies also aid in developing targeted therapies, such as uPA inhibitors or antibody-drug conjugates. Their specificity for different uPA forms (pro-enzyme, active, or complexes with inhibitors) enhances mechanistic insights into proteolytic cascades. As uPA’s dysregulation spans cancers, fibrosis, and cardiovascular diseases, PLAU antibodies remain vital for exploring its dual roles in physiology and disease, bridging translational research and clinical applications.
×
